Skip to main content

Table 3 Expression levels of biomarker candidates in serum collected from patients with NSCLC (n = 94) and healthy volunteer controls (n = 189)

From: Blood-based lung cancer biomarkers identified through proteomic discovery in cancer tissues, cell lines and conditioned medium

 

Control

Case

KS test (p-val)

AUC

Median: ng/mL

Median: ng/mL

(Interquartile range)

(Interquartile range)

CEA (CEACAM5)

1.65 (0.85-2.92)

2.68 (1.85-4.90)

<0.0001

0.706

MDK

0.15 (0.04-0.35)

0.43 (0.20-0.66)

<0.0001

0.714

MMP2

207 (184-234)

207 (171-254)

0.1472

0.492

SLPI

39.6 (34.8-46.2)

43.3 (35.5-54.5)

0.0036

0.595

TFPI

39.7 (25.6-55.1)

54.1 (29.1-70.3)

<0.0001

0.617

TIMP1

302 (269-346)

361 (306-440)

<0.0001

0.692

CYFRA 21-1

0.58 (0.00-1.05)

1.60 (0.91-3.00)

<0.0001

0.816

OPN

19.3 (10.0-31.0)

31.4 (16.7-52.4)

<0.0001

0.666

SCC

0.58 (0.34-0.93)

1.21 (0.55-1.70)

<0.0001

0.696

  1. Median levels (ng/mL) and interquartile range are shown. The Kolmogorov–Smirnov test (KS test) was used to compare patient groups. Area under the curve (AUC) calculated from receiver operator characteristic (ROC) curve analysis. Markers in the upper section of the table (n = 6) represent proteins resolved through MS analysis. The lower section (n = 3) represents well-characterized lung cancer biomarkers